AACR White Paper: Shaping the Future of Cancer Prevention - A Roadmap for Advancing Science and Public Health
Overview
Authors
Affiliations
The recent pace, extent, and impact of paradigm-changing cancer prevention science has been remarkable. The American Association for Cancer Research (AACR) convened a 3-day summit, aligned with five research priorities: (i) Precancer Atlas (PCA). (ii) Cancer interception. (iii) Obesity-cancer linkage, a global epidemic of chronic low-grade inflammation. (iv) Implementation science. (v) Cancer disparities. Aligned with these priorities, AACR co-led the Lancet Commission to formally endorse and accelerate the NCI Cancer Moonshot program, facilitating new global collaborative efforts in cancer control. The expanding scope of creative impact is perhaps most startling-from NCI-funded built environments to AACR Team Science Awarded studies of Asian cancer genomes informing global primary prevention policies; cell-free epigenetic marks identifying incipient neoplastic site; practice-changing genomic subclasses in myeloproliferative neoplasia (including germline variant tightly linked to JAK2 V617F haplotype); universal germline genetic testing for pancreatic cancer; and repurposing drugs targeting immune- and stem-cell signals (e.g., IL-1β, PD-1, RANK-L) to cancer interception. Microbiota-driven IL-17 can induce stemness and transformation in pancreatic precursors (identifying another repurposing opportunity). Notable progress also includes hosting an obesity special conference (connecting epidemiologic and molecular perspectives to inform cancer research and prevention strategies), co-leading concerted national implementation efforts in HPV vaccination, and charting the future elimination of cancer disparities by integrating new science tools, discoveries and perspectives into community-engaged research, including targeted counter attacks on e-cigarette ad exploitation of children, Hispanics and Blacks. Following this summit, two unprecedented funding initiatives were catalyzed to drive cancer prevention research: the NCI Cancer Moonshot (e.g., PCA and disparities); and the AACR-Stand Up To Cancer bold "Cancer Interception" initiative.
Evaluating DNA Methylation in Random Fine Needle Aspirates from the Breast to Inform Cancer Risk.
Visvanathan K, Cimino-Mathews A, Fackler M, Karia P, VandenBussche C, Orellana M Breast J. 2025; 2022:9533461.
PMID: 39741654 PMC: 11401740. DOI: 10.1155/2022/9533461.
A Blood-based Metabolite Signature for Personalized Risk Assessment of Pancreatic Cancer.
Leon-Letelier R, Chen Y, Ballaro R, Irajizad E, Do K, Maitra A J Cancer Immunol (Wilmington). 2024; 6(4):148-153.
PMID: 39713022 PMC: 11661815. DOI: 10.33696/cancerimmunol.6.095.
Hoffman R, Donze L, Agurs-Collins T, Belay B, Berrigan D, Blanck H Obes Rev. 2024; 25(9):e13769.
PMID: 38830619 PMC: 11309895. DOI: 10.1111/obr.13769.
A framework and process for community-engaged, mixed-methods cancer needs assessments.
Burus T, Thompson J, McAfee C, Williams L, Knight J, Huang B Cancer Causes Control. 2024; 35(10):1319-1332.
PMID: 38809305 PMC: 11461567. DOI: 10.1007/s10552-024-01892-2.
Fervers B, Perol O, Lasset C, Moumjid N, Vidican P, Saintigny P Cancer Prev Res (Phila). 2024; 17(4):133-140.
PMID: 38562091 PMC: 10985472. DOI: 10.1158/1940-6207.CAPR-23-0386.